AFYX Therapeutics AS

Today, we are happy to announce that Inphena A/S has acquired all shares in AFYX Therapeutics A/S. The transaction came in place after the majority shareholders Sofinnova, Novo Holdings and the Lundbeck Foundation decided that the transaction was in the best interest of all parties and that it would secure the continued development of the Rivelin Patch technology. Inphena A/S is a niche biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals. AFYX Therapeutics A/S – Our company is a niche biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and has secured successful IPOs of 3 other companies in the BioPharma Industry (OXiGENE, Inc., Genmab A/S and Y-mAbs Therapeutics, Inc) Our focus is: • OBSTETRICS • NICHE ONCOLOGY • PAIN AND ADDICTION Contact: inquiry@afyxtx.com | +45 7174 7174

ResMed touts study demonstrating impact of CPAP on chances of living longer ResMed (NYSE:RMD) is touting data highlighting the use of PAP therapy and its connection to potentially living longer. A late-breaking abstract presented at the virtual European Respiratory Society (ERS) International Congress 2021, supported by ResMed, found that using positive airway pressure (PAP) therapy as directed can significantly increase sleep apnea patients’ chances of living longer, according… […] Novocure wins FDA breakthough designation for liver tumor treatment device Novocure (NSDQ:NVCR) announced today that the FDA granted breakthrough designation for its NovoTTF-200T liver cancer treatment system. St. Helier, Jersey-based Novocure designed its NovoTTF-200T system, a tumor treating fields (TTFields) delivery system for use in tandem with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer. According to a… […] Madorra wins FDA breakthrough nod for home vulvovaginal atrophy treatment device Madorra this week said it has received FDA breakthrough device designation for its noninvasive, home-use device for moderate to severe vulvovaginal atrophy. Through the breakthrough device program, Madorra will have priority review and communication regarding the development of the device until the product goes on the market. Madorra’s handheld device is designed as a prescription,… […] Medtronic, Boston Scientific and Abbott fund new University of Minnesota Center for Medical Device Cybersecurity The University of Minnesota and medical device manufacturers have partnered to launch an organization for cybersecurity research, outreach and workforce training. Medtronic (NYSE:MDT) , Boston Scientific (NYSE: BSX), Abbott Laboratories (NYSE:ABT) , Smiths Medical and UnitedHealth Group’s (NYSE: UNH) Optum contributed financial support as founding partners of the University of Minnesota Center for Medical Device… […] Elizabeth Holmes trial opens, accused of ‘lying and cheating’ Ex-Theranos CEO Elizabeth Holmes’ federal fraud trial began with federal prosecutors claiming she lied and cheated to get money. The prosecutors alleged on opening day yesterday that Holmes was manipulative and knowingly defrauded investors and patients through false and misleading claims, according to media reports. “This is a case about fraud, about lying and cheating… […] Stryker completes Gauss Surgical acquisition Stryker (NYSE:SYK) announced today that it acquired Gauss Surgical and its Triton platform for an undisclosed amount. Menlo Park, California-based Gauss Surgical designed the Triton artificial intelligence-enabled platform for the real-time monitoring of blood loss during surgery. The platform has demonstrated improvements in maternal and surgical care through earlier recognition of hemorrhage leading to earlier intervention, according to… […] Medtronic releases Navablate study results for bronchoscopic microwave ablation Medtronic (NYSE:MDT) reported new clinical data from its Navablate study of bronchoscopic microwave ablation with its Emprint ablation catheter kit to treat malignant lung nodules. “Patients with malignant lesions in the lung often have limited therapy options due to lesion locations, comorbidities and treatment side effects,” said one of the principal investigators, Kelvin Lau —… […] AFYX touts trial of biodegradable drug delivery patch AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology. The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases. Get the full story at our sister site,… […] FDA approves TransMedics’ OCS Heart system TransMedics (NSDQ:TMDX) announced today that it received FDA premarket approval for its OCS Heart system. Andover, Massachusetts-based TransMedics designed its OCS Heart system for use with organs from donors after brain death with indication for preserving donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of prolonged cold static cardioplegic preservation,… […] Jurors selected in Elizabeth Holmes’ Theranos fraud trial; start date set The jurors who will weigh the evidence for and against Theranos founder Elizabeth Holmes were sworn in Thursday, setting the stage for the federal fraud trial to finally begin. The twelve jurors — seven men and five women, all residents of California’s Santa Clara County — were selected along with five alternates (two men and three… […]

The preclinical study shows potential to deliver anti-TNFα antibody fragments to inflamed mucosal tissue using Rivelin technology Rivelin Patch shows superior results in preclinical study. (Credit: Chokniti Khongchum from Pixabay.) AFYX Therapeutics has unveiled positive results from a preclinical study, exploring the potential of its Rivelin patch technology in delivering antibody fragments. The study, conducted in collaboration with the UK’s University of Sheffield, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue to treat mucosal diseases. Rivelin is a mucoadhesive two-layered patch that delivers a pharmaceutical product directly to wet tissue surfaces. Leveraging a unique patch technology, Rivelin adheres to mucosal surfaces for long periods and facilitates uni-directional delivery of a pharmaceutical agent selectively to the target site. The patch is designed to limit the delivery of drug substances to areas surrounding the target site, enabling high efficacy, low dosing and less toxicity to non-affected parts. AFYX Therapeutics CEO Nishan de Silva said: “The recent presentation features the first Rivelin study demonstrating the potential to deliver not only small molecules but also proteins – in this case, anti-TNFα antibody fragments. “Delivering antibodies to target inflammatory disease in the oral mucosa using the Rivelin patch technology allows the development of new, locally-delivered therapies for mucosal diseases that currently can only be addressed with systemic treatment modalities. “Future studies will evaluate higher doses with potential to achieve complete neutralisation, and will aim to deliver anti-TNFα fragments topically to inflamed tissue in oral mucosal models.” In the study, the Rivelin patch was formulated with therapeutic anti-TNFα antibody fragments, where a biotinylated F(ab) fragment was electrospun into the existing Rivelin formulation. The results showed that the antibodies were delivered directly to inflamed mucosal tissue, while maintaining antigen-binding activity. Also, a low dose of anti-TNF F(ab)s reduced IL8 expression compared to placebo, showing that the F(ab) maintained neutralising activity on inflammatory cells, after release. AFYX said that the preclinical study, for the first time, showed that the Rivelin technology is capable of delivering biologic drugs. Also, the technology would significantly improve the treatment model for oral lichen planus and other inflammatory mucosal diseases. In a Phase 2 study, Rivelin-CLO 20-μg dose showed a statistically significant improvement in ulcer size in patients with oral lichen planus, a condition with no FDA approved therapy.